A sweeping analysis of medical marketing in the U.S. — from drug promotions aimed at consumers and physicians to disease awareness campaigns, hospital services, and laboratory testing — found a 69 percent increase, to $29.9 billion, over a recent 20-year period. But despite policies designed to limit industry influence over the health care system, there appeared to be insufficient regulatory oversight.

The fastest rise in industry marketing was spent on direct-to-consumer ads, which increased from $2.1 billion, or 12 percent, of all marketing expenditures in 1997, to $9.6 billion, or 32 percent of total spending in 2016, according to the analysis in the Journal of the American Medical Association. During that period, the number of times TV commercials aired for medicines jumped from 663,000 to 4.6 million.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • This is the big secret that no one is investigating. Health outcomes are worse than they were before this kind of deceptive marketing was allowed. Prior to 1996 this kind of marketing was Illegal. Now that there is even less regualtion, it has gotten worse. Industry Insiders at the FDA, and the FTC refuse to investigate false claims, misnformation and outright lies.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy